| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product sales, net | $9.0M+4.0% | $8.6M-12.2% | $9.8M+11.6% | $8.8M-14.5% | $10.3M+89.5% | $5.4M |
| Cost of products sold | $2.6M+16.9% | $2.2M-27.7% | $3.0M-22.3% | $3.9M-2.2% | $4.0M+119.9% | $1.8M |
| Gross profit | $6.4M-0.4% | $6.4M-5.3% | $6.8M+38.6% | $4.9M-22.4% | $6.3M+74.3% | $3.6M |
| Selling, general and administrative expenses | $11.6M-5.8% | $12.3M-6.4% | $13.1M+5.0% | $12.5M-1.8% | $12.7M+19.4% | $10.7M |
| Research and development expenses | $449K-47.7% | $859K+22.4% | $701K-39.0% | $1.2M+31.0% | $878K+185.3% | $308K |
| Depreciation and amortization expense | $78K+108.8% | $37K-39.5% | $62K-2.9% | $64K-13.7% | $74K-23.0% | $96K |
| Total operating expenses | $12.1M-8.2% | $13.2M-5.1% | $13.9M+1.2% | $13.7M+0.3% | $13.7M+23.6% | $11.1M |
| Loss from operations | -$5.7M+15.7% | -$6.8M+4.9% | -$7.1M+19.5% | -$8.8M-19.6% | -$7.4M+1.0% | -$7.5M |
| Interest (expense) income, net | -$26K-142.5% | $60K | — | — | — | — |
| Gain on sale of net operating losses | $2.0M | — | $0 | — | — | — |
| Loss before provision for income taxes | -$5.7M-21.4% | -$4.7M+32.5% | -$7.0M+20.4% | -$8.8M | — | — |
| Provision for income taxes | — | — | — | $0+100.0% | -$333+97.9% | -$16K |
| Net loss | -$5.7M-21.4% | -$4.7M+32.5% | -$7.0M+20.4% | -$8.8M-27.6% | -$6.9M+6.9% | -$7.4M |
| Net loss per share applicable to common stockholders - basic | -$0.07-16.7% | -$0.06+40.0% | -$0.10+16.7% | -$0.12-20.0% | -$0.10+16.7% | -$0.12 |
| Net loss per share applicable to common stockholders - diluted | -$0.07-16.7% | -$0.06 | — | — | — | -$0.12 |
| Weighted average shares outstanding and to be issued - basic | 82.1M+2.8% | 79.8M+9.6% | 72.8M+3.1% | 70.6M+2.6% | 68.8M+9.1% | 63.1M |
| Weighted average shares outstanding and to be issued - diluted | 82.1M+2.8% | 79.8M | — | — | 68.8M+9.1% | 63.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.